肝动脉化疗栓塞术联合甘露聚糖肽治疗中晚期肝癌疗效观察.docVIP

肝动脉化疗栓塞术联合甘露聚糖肽治疗中晚期肝癌疗效观察 　【摘要】 目的 对比单纯肝动脉化疗栓塞术（TACE）与TACE联合甘露聚糖肽治疗中晚期肝癌的临床效果。方法 96例中晚期肝癌患者分为两组，A组：48例行单纯TACE治疗；B组：48例行甘露聚糖肽+TACE治疗，比较两组病人的疗效及毒副作用。结果 总有效率：A组为39.6%，B组为55.4%；一年存活率A组为39.6%，B组为55.8%；A组主要副作用为轻至中度的白细胞下降、肝功能损害等，B组主要副作用为发热、轻度的白细胞下降和肝功能损害等。结论 B组的疗效明显优于A组，甘露聚糖肽联合TACE是治疗中晚期肝癌的疗效显著的方法之一，副作用较少，改善了患者的肝功能，值得推广。 【关键词】 原发性肝癌；肝动脉化疗栓塞术；甘露聚糖肽 　　ABSTRACT Objective To compare the curative effect of TACE and TACE combined with mannatide injection in treating the patients with hepatic cancer at intermediate-advanced stage. Methods 96 cases with hepatic cancer at intermediate-advanced stage were divided into 2 groups: Group A (n=48) and Group B (n=48); only TACE was performed to patients in Group A, TACE combined with maddatide injection were given to patients in Group B; the curative effect and the side-effect were studied. Results The total effective rate of Group A was 39.6% while that of Group B was 55.4%; the survival rate of Group A was 39.6% while that of Group B was 55.8%; the main side-effects in Group A were light to medium leucopenia and hepatic function damage while those in Group B were fever, light leucopenia and hepatic function damage, the curative effect in Group A was much superior to that in Group B. Conclusions TACE combined with maddatide injection is effective in treating intermedium-advanced hepatic cancer with less side-effects and can improve the hepatic function of the patients. 　　KEYWORDS primary hepatic cancer TACE maddatide 　　原发性肝癌(以下简称肝癌)的首选治疗方法为手术切除，但是由于大多数患者就诊时已经处于中晚期，失去了手术机会，所以非手术切除的方法在肝癌的治疗中仍占有非常重要的地位，其中肝动脉化疗栓塞术(Transcatheter arterial chemoembolization，TACE)由于疗效明确，副作用相对较轻，在临床上得到广泛的应用。2001年5月～2003年5月，我院收治中、晚期肝癌96例，分别给予单纯肝动脉化疗栓塞术（TACE）与甘露聚糖肽(多抗)联合TACE治疗，疗效对比差异显著，现报告如下。 　　1 材料与方法 　　1.1 一般资料 按《新编常见恶性肿瘤诊治规范》标准,96例均经B超、CT、MRI、肝动脉造影、AFP检查，确诊为不能手术切除的中晚期肝癌患者，其中男:女为3:1，年龄25～68岁，中位年龄43.7岁。随机分为两组，每组48例，接受单纯肝动脉化疗栓塞术（TACE）为A组，甘露聚糖肽+TACE联合治疗组为B组。A、B两组患者基本情况差异无统计学意义。 　　1.2 治疗方法 A组：主要单纯肝动脉化疗栓塞术治疗，同时给予保肝等对症支持治疗。B组：除给予TACE治疗、对症支持治疗外，